Preparation and Distribution of Adult Stem Cells

成体干细胞的制备和分布

基本信息

批准号：
8472687
负责人：
DARWIN Johnson PROCKOP
金额：
$ 98.38万
依托单位：
TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-06-15 至 2018-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8472687
关键词：
Address Adult Age Aliquot Anti-Inflammatory Agents Anti-inflammatory Apoptosis Benchmarking Bioinformatics Bone Marrow Cell Count Cell surface Cells Clinic Clinical Trials Colony-forming units Data Data Analyses Electronic Mail Freezing Funding Gender Gene Proteins Genes Grant Green Fluorescent Proteins Human Human Volunteers Hypoxia Immune In Vitro Institutes Laboratories Letters Literature Luciferases Marrow Mesenchymal Mesenchymal Stem Cells Mitochondria Mouse Strains Mus Oxygen Population Preparation Principal Investigator Property Protocols documentation PubMed Rat Strains Rattus Reference Standards Regulator Genes Research Research Personnel Rodent Scientist Signal Transduction Source Standard Preparations Stem cells Strategic Planning Stromal Cells Subfamily lentivirinae System Telephone Testing Transgenic Organisms United States National Institutes of Health Variant Vial device adult stem cell base cytokine efficacy testing functional outcomes in vivo interest meetings prevent programs public health relevance rapid growth red fluorescent protein research study stem

项目摘要

DESCRIPTION (provided by applicant): This a competing renewal application (Type 2) for a Center to prepare adult stem/progenitor cells from the bone marrow of human volunteers and rodents, define the quality of the cells, and then distribute them to multiple investigators. The adult stem/progenitor cells we prepare were originally referred to as fibroblastic colony-forming-units, then as marrow stromal cells in the hematological literature, subsequently as mesenchymal stem cells, and most recently as multipotent mesenchymal stromal cells or MSCs. Since the last competitive renewal, we made 627 shipments of 1,075 vials of frozen MSCs to over 280 scientists of whom 157 are funded by 18 NIH Institutes. We have received over 140 Letters of Support. The Aims are: (1) To continue to produce standardized preparations of human MSCs (hMSCs) for distribution to other investigators. We will transduce some of the hMSCs with lentiviruses to express genes useful in tracking the cells both in culture and in vivo: with cytoplasmic green fluorescent protein (GFP), mitochondrial red fluorescent protein (MitoRed) and luciferase. (2) To continue to provide similar preparations of mouse MSCs (mMSCs) for distribution to other investigators. (3) To continue to provide similarly characterized preparations of rat MSCs (rMSCs) for distribution to other investigators. We will continue to prepare rMSCs from other rat strains and from transgenic rats ubiquitously expressing GFP as a marker for experiments in culture and in vivo. (4) In exploratory research (up to 10% of allocated funds), we will compare the genes expressed by different standard preparations of hMSCs and hMSCs pre-activated in culture by cytokines using microarrays, qRT-PCR and ELISAa for secreted factors. The data will be analyzed to identify the preparations with the highest levels of expression of anti-inflammatory and immune regulatory genes. The results will be provided to recipients of the hMSCs and scientists will be encouraged to compare preparations that the data suggest may vary in efficacy in the systems they are testing. We will provide assistance from a collaborating expert in bioinformatics in evaluating the data.

描述（由申请人提供）：这是一项竞争性更新申请（类型 2），目的是从人类志愿者和啮齿动物的骨髓中制备成体干细胞/祖细胞，确定细胞的质量，然后将其分发给多名研究人员。我们制备的成体干/祖细胞最初被称为成纤维细胞集落形成单位，然后在血液学文献中被称为骨髓基质细胞，随后被称为间充质干细胞，最近被称为多能间充质基质细胞或MSC。自上次竞争性更新以来，我们已向 280 多名科学家运送了 627 批 1,075 瓶冷冻 MSC，其中 157 名科学家由 18 个 NIH 研究所资助。我们已收到 140 多封支持信。目标是： (1) 继续生产人类 MSC (hMSC) 的标准化制剂，以分发给其他研究人员。我们将用慢病毒转导一些 hMSC，以表达可用于在培养物和体内追踪细胞的基因：细胞质绿色荧光蛋白 (GFP)、线粒体红色荧光蛋白 (MitoRed) 和荧光素酶。 (2) 继续提供类似的小鼠间充质干细胞（mMSCs）制剂，分发给其他研究者。 (3) 继续提供具有相似特征的大鼠间充质干细胞（rMSCs）制剂，以分发给其他研究人员。我们将继续从其他大鼠品系和普遍表达 GFP 的转基因大鼠中制备 rMSC，作为培养和体内实验的标记。 (4) 在探索性研究中（最多分配资金的10%），我们将使用微阵列、qRT-PCR和分泌因子ELISAa来比较不同标准的hMSCs和通过细胞因子在培养物中预激活的hMSCs表达的基因。将对数据进行分析，以确定抗炎和免疫调节基因表达水平最高的制剂。结果将提供给 hMSC 的接受者，并鼓励科学家比较数据表明在他们正在测试的系统中功效可能有所不同的制剂。我们将提供生物信息学合作专家的协助来评估数据。